Remove 2019 Remove Documentation Remove Labelling
article thumbnail

How to get insurance to cover Ozempic for weight loss

The Checkup by Singlecare

In fact, the drug often sees shortages due to high demand for off-label prescriptions for weight loss. Although some healthcare providers prescribe Ozempic off-label for weight loss, insurance often won’t cover Ozempic for these uses unless it’s medically justified and no alternative treatments exist.

article thumbnail

Is Latuda covered by Medicare?

The Checkup by Singlecare

It’s also sometimes prescribed off-label to treat major depressive disorder and other mental health conditions. In 2019, the FDA approved a generic version of Latuda (lurasidone) , which just became available in 2023. This is why “ensuring patients have the proper documentation is crucial,” says Sazan Sylejmani, Pharm.D.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Change is Inevitable – Plan Ahead: An Assessment of FDA’s Draft Guidance on Predetermined Change Control Plans for Artificial Intelligence/Machine Learning-Enabled Device Software Functions

The FDA Law Blog

a) , and related guidance documents (e.g., Post-market, manufacturers can make modifications consistent with the PCCP and document the modification in accordance with their quality system, without the need for a new marketing submission. See 21 CFR 807.81(a)(3) a)(3) and 21 CFR 814.39(a)

FDA 98
article thumbnail

How to get Ozempic prescribed for weight loss

The Checkup by Singlecare

Weight loss is an off-label , non-FDA-approved use for Ozempic. Because Ozempic is currently approved by the FDA for only diabetes management, health insurance plans are unlikely to cover the prescription medication for off-label uses such as weight loss. In fact, in clinical trials, patients taking Ozempic were able to lose 10.9%

Insurance 104
article thumbnail

The Incredible Shrinking Exemption: FDA Final CDS Guidance Would Significantly Narrow the Scope of Exempt Clinical Decision Support Software Under the Cures Act

The FDA Law Blog

Javitt — On September 28, 2022, the FDA issued the long anticipated final Clinical Decision Support Software Guidance (CDS Guidance), which replaces the revised draft guidance document from 2019. FDA gives no rationale for interpreting the apparently broad statutory term “medical information” in such a restrictive manner.

FDA 52
article thumbnail

Long-Awaited Guidance on FDAMA 115: Confirmatory Evidence Finally Has Its Moment (to be Crossed Off the FDA’s Guidance To-Do List)

The FDA Law Blog

The new guidance is one of three policy documents dedicated to explaining FDA’s interpretation of this statutory authority and their approach to exercising scientific judgment in evaluating drug effectiveness. We are heartened to see that this latest guidance reflects many of the advances we observed in practice since 2019.

FDA 64
article thumbnail

Is Confirmatory Evidence Having a Moment?

The FDA Law Blog

Additional guidance on confirmatory evidence is sorely needed as the December 2019 draft guidance spends just two of its 18 pages telling us what FDA thinks of such a key piece of statutory language. However, we wonder whether recent and ongoing approval decisions are shaping FDA’s thinking, possibly pushing back issuance of a draft.

FDA 61